Lee Joon K, Mahan Meredith, Hanna Rabbie K, Elshaikh Mohamed A
Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, United States.
Department of Public Health Science, Henry Ford Hospital, Detroit, MI, United States.
Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:192-197. doi: 10.1016/j.ejogrb.2017.08.001. Epub 2017 Aug 2.
Para-aortic lymph node involvement in women with endometrial carcinoma (EC) is a poor prognostic factor. Many studies have included women with stage IIIC in cohorts of patients with advanced stage disease. The aim of this study was to analyze survival outcomes and patterns of failure in women with solely stage IIIC EC.
We identified women with FIGO stage IIIC EC who underwent surgical staging at our institution. In addition to descriptive analyses of patient demographics, tumor characteristics, and adjuvant treatment received, univariate log-rank analyses and Cox regression multivariate analyses (MVA) were performed to identify predictors of recurrence-free (RFS), disease-specific (DSS) and overall survival (OS).
A total of 72 women were included in this study cohort. The median follow-up time was 43 months. The median number of positive para-aortic lymph nodes was one. Of the 61 women (84.7%) who received adjuvant therapy, 40 women (65.6%) received chemotherapy and radiation therapy (CRT), 17 women (27.9%) received chemotherapy alone (CT), and only 4 women (6.6%) received radiation therapy alone. Thirty-seven women (51.4%) experienced disease recurrence. Distant metastasis was the most common pattern of failure (73%). Five-year RFS, DSS, and OS were 48%, 51%, and 48%, respectively. Due to small study size, our exploratory multivariate analysis demonstrated that histologic grade was the only significant prognostic factor for DSS (p=0.03) and OS (p=0.02). The type of adjuvant therapy did not sustain its independent predictive significance for RFS, DSS and OS.
Our findings suggest that almost half of women with stage IIIC can be cured with surgical staging and adjuvant therapies. The most common pattern of failure was distant metastasis calling for further optimization of systemic therapy.
子宫内膜癌(EC)女性患者的腹主动脉旁淋巴结受累是一个不良预后因素。许多研究将IIIC期女性纳入晚期疾病患者队列中。本研究的目的是分析单纯IIIC期EC女性患者的生存结局和失败模式。
我们确定了在本机构接受手术分期的FIGO IIIC期EC女性患者。除了对患者人口统计学、肿瘤特征和接受的辅助治疗进行描述性分析外,还进行了单变量对数秩分析和Cox回归多变量分析(MVA),以确定无复发生存期(RFS)、疾病特异性生存期(DSS)和总生存期(OS)的预测因素。
本研究队列共纳入72名女性。中位随访时间为43个月。腹主动脉旁阳性淋巴结的中位数为1个。在接受辅助治疗的61名女性(84.7%)中,40名女性(65.6%)接受了化疗和放疗(CRT),17名女性(27.9%)仅接受了化疗(CT),只有4名女性(6.6%)仅接受了放疗。37名女性(51.4%)出现疾病复发。远处转移是最常见的失败模式(73%)。5年RFS、DSS和OS分别为48%、51%和48%。由于研究规模较小,我们的探索性多变量分析表明,组织学分级是DSS(p=0.03)和OS(p=0.02)的唯一显著预后因素。辅助治疗类型对RFS、DSS和OS不再具有独立的预测意义。
我们的研究结果表明,几乎一半的IIIC期女性患者可通过手术分期和辅助治疗治愈。最常见的失败模式是远处转移,需要进一步优化全身治疗。